Pre-Chemo Abiraterone + Prednisone Combo Proves Effective for CRPC

The FDA recently approved a combination of two drugs—abiraterone and the steroid prednisone—for the treatment of castration-resistant prostate cancer (CRPC) in patients who have previously been treated with chemotherapy. Scientists are now testing whether the combination treatment is beneficial for patients who have not been treated with chemotherapy. Interim results indicate that the treatment doubles progression-free survival and increases overall survival from 30.1 months to 35.3 months.

Two Phase III Prostate Cancer Trials Miss Their Mark

Researchers at the 2013 Genitourinary Cancers Symposium presented the results of two negative phase III studies—READY and VENICE—of targeted agents that failed to increase overall survival  when combined with standard first-line chemotherapy docetaxel/prednisone for the treatment of men with metastatic castration-resistant prostate cancer.The two agents are aflibercept and dasatinib. 

New Phase III study will test BRAF/MEK combination therapy in melanoma patients with BRAF positive mutation after following surgery

The London-based company, GSK has stared a phase III trial called “COMBI-AD” that will test the combination of a BRAF and MEK inhibitor, dabrafenib and trametinib in patients with BRAF V600E mutation-positive melanoma who have had surgery to remove their tumors (adjuvant setting). The placebo-controlled trial is testing how long the combo treatment can delay or prevent cancer recurrence in these high-risk patients. Two phase III combination trials are currently ongoing to test the combination versus monotherapy in metastatic BRAF-positive melanoma patients. 

Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study

Combination of bevacizumab and weekly paclitaxel showed synergitic effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has never been evaluated in non small cell lung cancer (NSCLC). We retrospectively reviewed safety and efficacy of this regimen in metastatic non-squamous NSCLC as fourth-line therapy or beyond.

In our experience, combination of bevacizumab and weekly paclitaxel exhibited acceptable toxicity and had encouraging anti-tumor efficacy as fourth-line treatment or beyond for non-squamous NSCLC patients, supporting further evaluation in larger prospective studies.

Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. The combination of everolimus and docetaxel was tolerated well, but the efficacy was relatively modest in an unselected population of patients with NSCLC.

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

New study suggests the combination of  targeting  the MEK/ERK and PI3K/mTOR pathways has antitumor activity and could be a therapeutic option in the treatment of NRAS mutant melanoma, for which there are currently no effective therapies.

Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial

The combination pemetrexedcarboplatin could be a valuable treatment option in elderly patients, as indicated by this phase II trial. Neutropenia was the most common toxicity. The objective tumor response rate is within the range of data reported for pemetrexedcarboplatin in the general NSCLC population.

Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.

Combined BRAF and MEK Inhibition Improves Outcome in Metastatic Melanoma

The combination of dabrafenib and trametinib is safe and effective in BRAF-mutant melanoma.